MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC
Author:
Publisher
Elsevier BV
Subject
Genetics,General Medicine
Reference40 articles.
1. Mcl-1 is a potential therapeutic target in multiple types of cancer;Akgul;Cell. Mol. Life Sci.,2009
2. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA;Albershardt;J. Biol. Chem.,2011
3. Bcl-2 inhibitors: emerging drugs in cancer therapy;Bodur;Curr. Med. Chem.,2012
4. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer;Chiappori;J. Thorac. Oncol.,2014
5. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation;Choi;PLoS ONE,2015
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity;Nature Cancer;2024-09-11
2. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models;Nature Cancer;2024-08-23
3. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway;Canadian Respiratory Journal;2024-03-04
4. Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL‑1;Oncology Letters;2024-01-05
5. Cancer Resistance Is Mediated by the Upregulation of Several Anti-Apoptotic Gene Products via the Inducible Nitric Oxide Synthase/Nitric Oxide Pathway: Therapeutic Implications;Antioxidants & Redox Signaling;2023-11-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3